These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 22785114

  • 1. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.
    Stallone G, Infante B, Grandaliano G, Bristogiannis C, Macarini L, Mezzopane D, Bruno F, Montemurno E, Schirinzi A, Sabbatini M, Pisani A, Tataranni T, Schena FP, Gesualdo L.
    Nephrol Dial Transplant; 2012 Sep; 27(9):3560-7. PubMed ID: 22785114
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
    Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wüthrich RP.
    Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
    [Abstract] [Full Text] [Related]

  • 3. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
    Zeltner R, Poliak R, Stiasny B, Schmieder RE, Schulze BD.
    Nephrol Dial Transplant; 2008 Feb; 23(2):573-9. PubMed ID: 17984104
    [Abstract] [Full Text] [Related]

  • 4. Sirolimus for treatment of autosomal-dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
    Liu YM, Shao YQ, He Q.
    Transplant Proc; 2014 Feb; 46(1):66-74. PubMed ID: 24507028
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.
    Ruggenenti P, Gentile G, Perico N, Perna A, Barcella L, Trillini M, Cortinovis M, Ferrer Siles CP, Reyes Loaeza JA, Aparicio MC, Fasolini G, Gaspari F, Martinetti D, Carrara F, Rubis N, Prandini S, Caroli A, Sharma K, Antiga L, Remuzzi A, Remuzzi G, SIRENA 2 Study Group.
    Clin J Am Soc Nephrol; 2016 May 06; 11(5):785-794. PubMed ID: 26912555
    [Abstract] [Full Text] [Related]

  • 9. Effect of Sirolimus on Native Total Kidney Volume After Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Pilot Study.
    Davis S, Gralla J, Chan L, Wiseman A, Edelstein CL.
    Transplant Proc; 2018 Jun 06; 50(5):1243-1248. PubMed ID: 29880342
    [Abstract] [Full Text] [Related]

  • 10. [Autosomal dominant polycystic kidney disease (ADPKD): rapamycin as a new treatment option].
    Serra AL, Wüthrich RP.
    Praxis (Bern 1994); 2009 Dec 16; 98(25):1511-6. PubMed ID: 20013687
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Everolimus in patients with autosomal dominant polycystic kidney disease.
    Walz G, Budde K, Mannaa M, Nürnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hörl WH, Obermüller N, Arns W, Pavenstädt H, Gaedeke J, Büchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU.
    N Engl J Med; 2010 Aug 26; 363(9):830-40. PubMed ID: 20581392
    [Abstract] [Full Text] [Related]

  • 14. Long-term treatment with mammalian target of rapamycin inhibitor does not benefit patients with autosomal dominant polycystic kidney disease: a meta-analysis.
    Xue C, Dai B, Mei C.
    Nephron Clin Pract; 2013 Aug 26; 124(1-2):10-6. PubMed ID: 24022660
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study.
    Braun WE, Schold JD, Stephany BR, Spirko RA, Herts BR.
    Clin J Am Soc Nephrol; 2014 May 26; 9(5):881-8. PubMed ID: 24721888
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease.
    Zafar I, Ravichandran K, Belibi FA, Doctor RB, Edelstein CL.
    Kidney Int; 2010 Oct 26; 78(8):754-61. PubMed ID: 20686448
    [Abstract] [Full Text] [Related]

  • 19. Sirolimus produced S-shaped effect on adult polycystic kidneys after 2-year treatment.
    Soliman A, Zamil S, Lotfy A, Ismail E.
    Transplant Proc; 2012 Dec 26; 44(10):2936-9. PubMed ID: 23195001
    [Abstract] [Full Text] [Related]

  • 20. Monitoring biological action of rapamycin in renal transplantation.
    Leogrande D, Teutonico A, Ranieri E, Saldarelli M, Gesualdo L, Schena FP, Di Paolo S.
    Am J Kidney Dis; 2007 Aug 26; 50(2):314-25. PubMed ID: 17660033
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.